The study found that men in their 40s and 50s with a baseline PSA at or above the median PSA were much more likely to undergo a biopsy and be diagnosed with low-risk prostate cancer. However, the majority of tumors (89 percent) found in both age groups were classified as “low risk.”
The study’s findings are being released soon after the U.S. Preventive Services Task Force published draft recommendations that the test may not save lives.
Related Articles on the Mayo Clinic:
Mayo Clinic Provides Guidance on Using Therapeutic Cooling for Sudden Cardiac Arrest
Mayo Clinic Partners With Researchers in India
Arizona’s Kingman Regional Joins Mayo Clinic Care Network
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
